Fragment-based deconstruction of Bcl-xL inhibitors.

@article{Barelier2010FragmentbasedDO,
  title={Fragment-based deconstruction of Bcl-xL inhibitors.},
  author={Sarah Barelier and Julien Pons and Olivier Marcillat and Jean-Marc Lancelin and Isabelle Krimm},
  journal={Journal of medicinal chemistry},
  year={2010},
  volume={53 6},
  pages={2577-88}
}
Fragment-based drug design consists of screening low-molecular-weight compounds in order to identify low-affinity ligands that are then modified or linked to yield potent inhibitors. The method thus attempts to build bioactive molecules in a modular way and relies on the hypothesis that the fragment binding mode will be conserved upon elaboration of the active molecule. If the inverse process is considered, do the fragments resulting from the deconstruction of high-affinity inhibitors… CONTINUE READING

From This Paper

Topics from this paper.
20 Citations
0 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 20 extracted citations

Similar Papers

Loading similar papers…